Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim236 enrolled

Overview

New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®

Study Type

OBSERVATIONAL

Enrollment

236

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Berodual® Respimat® - inhalerDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients aged at least 18 years who were suffering from symptoms of a COLD (naive or pre-treated) could be included in the PMS Exclusion Criteria: * Patients who meet one or more of the general or specific contraindications mentioned in the Summary of Product Characteristics (SmPC) are excluded from the Postmarketing Surveillance (PMS)

Outcomes

Primary Outcomes

Number of patients with adverse events

Time frame: up to 8 weeks

Number of patients who premature discontinued therapy with Berodual® Respimat®

Time frame: up to 8 weeks

Secondary Outcomes

Assessment of patient satisfaction with regard to handling of Berodual® Respimat® inhaler

by means of patient satisfaction and preference questionnaire (PASAPQ)

Time frame: up to 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.